DOC
Real EstateHealthpeak Properties
Price Chart
Market Data
Financials
XBRL · SEC EDGAR2007–2025(19yr)| Metric | FY 2007 | FY 2008 | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025Latest | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $953.7M | $1.2B | $1.2B | $1.3B | $1.7B | $1.9B | $2.1B | $2.3B | $2.5B | $2.1B | $1.8B | $1.8B | $2.0B | $1.6B | $1.9B | $2.1B | $2.2B | $2.7B | $2.8B | +4.5% |
| Net Income | $614.1M | $448.5M | $131.7M | $330.7M | $538.9M | $832.5M | $970.8M | $922.2M | -$559.2M | $627.7M | $414.2M | $1.1B | $45.5M | $413.6M | $505.5M | $500.4M | $306.0M | $243.1M | $71.3M | -70.7% |
| FFO | $872.4M | $761.9M | $451.3M | $642.7M | $895.7M | $1.2B | $1.4B | $1.4B | -$48.5M | $1.2B | $948.9M | $1.6B | $705.5M | $967.5M | $1.2B | $1.2B | $1.1B | $1.3B | $1.1B | -13.1% |
| FFO Margin | 91.5% | 66.1% | 39.0% | 51.2% | 51.9% | 62.6% | 66.4% | 61.0% | -1.9% | 56.2% | 51.3% | 87.2% | 35.3% | 58.8% | 62.7% | 58.8% | 48.4% | 48.2% | 40.0% | -8.1pp |
| Net Margin | 64.4% | 38.9% | 11.4% | 26.3% | 31.2% | 43.8% | 46.2% | 40.7% | -22.0% | 29.5% | 22.4% | 57.5% | 2.3% | 25.1% | 26.7% | 24.3% | 14.0% | 9.0% | 2.5% | -6.5pp |
| EPS (Diluted) | $2.70 | $1.79 | $0.40 | $1.00 | $1.29 | $1.90 | $2.13 | $2.00 | $-1.21 | $1.34 | $0.88 | $2.24 | $0.09 | $0.77 | $0.93 | $0.92 | $0.56 | $0.36 | $0.10 | -72.2% |
1. THE BIG PICTURE
Healthpeak Properties is currently a company in transition, attempting to shed its "senior housing" skin to emerge as a specialized provider of life science and outpatient medical infrastructure. This pivot is a response to the public market’s inability to properly value its diverse portfolio, but the success of the strategy rests on whether management can reignite growth in its lab segment, which has recently stalled.
2. WHERE THE RISKS HIT HARDEST
Healthpeak’s stated advantage in scale and industry relationships is directly threatened by tenant financial viability risks. While Healthpeak Properties prides itself on deep ties to biotechnology and healthcare systems (Business), these same tenants are facing "site-neutral" payment initiatives and reduced government funding (Risks). If these regulatory pressures impair tenant liquidity, Healthpeak’s scale becomes a liability, increasing the likelihood of lease rejections or unfavorable contract amendments.
Furthermore, the capital recycling strategy—selling stabilized assets to fund high-growth developments—is hindered by macroeconomic volatility. Management’s goal to redeploy capital into strategic life science campuses (Recent Results) is complicated by elevated interest rates, which make it "more challenging" to identify acquisitions that meet investment objectives (Competitive Position). This creates a squeeze where Healthpeak Properties may sell assets but find the replacement "growth" opportunities too expensive to be accretive.
3. WHAT THE NUMBERS SAY TOGETHER
The financial data reveals a stark divergence between headline earnings and underlying segment health. While net income rose to $113.8 million in Q4 2025 from just $4.4 million a year prior, this was accompanied by a (0.3%) contraction in Lab segment Same-Store Cash NOI (Recent Results). This suggests that while Healthpeak Properties is profitable on paper, its core growth engine for the post-spinoff era is currently idling.
Compared to its peers, Healthpeak operates with a thin 1.5% net margin—the lowest in the group—contrasting sharply with KIM’s 27.1% (Peer Benchmarking). This margin compression is likely a byproduct of Healthpeak Properties’s RIDEA structures, where Healthpeak bears direct operational risks and labor costs for senior housing (Competitive Position). Short interest stands at 6.0% of the float, or 31.2 million shares (Supplemental Signals), indicating that a meaningful portion of the market remains unconvinced by management’s "inflection point" narrative for the life science sector.
4. IS IT WORTH IT AT THIS PRICE?
At a P/FFO of 10.8x, Healthpeak trades at a 23% discount to the peer median of 14.1x (Peer Benchmarking). According to the (CAPM analysis), the market is pricing in a 1.2% long-term growth rate. This valuation is "attractively valued" only if one believes management can successfully execute the Janus Living IPO and reverse the negative growth in the lab segment.
The 7.0% dividend yield is the highest in the peer group, nearly triple VTR’s 2.4% (Peer Benchmarking). However, this high yield often signals market concern regarding the sustainability of growth or the complexity of the upcoming spinoff. If long-term growth were to align with a standard GDP pace of 2.5%, the justified P/FFO would rise to 12.6x (CAPM analysis). For now, the discount is justified by the (0.3%) decline in lab performance and the "relative lack of guidance" in the regulatory environment for its operators.
5. WHAT WOULD CHANGE THIS VIEW?
- Constructive if the Lab segment returns to positive Same-Store Cash NOI growth, validating management’s claim that fundamentals are at an inflection point.
- Constructive if the Janus Living IPO is completed at a valuation that allows Healthpeak to significantly reduce its $9.0 billion net debt load.
- Cautious if 2026 FFO per share falls toward the lower end of the $1.70 guidance range, suggesting that capital recycling is failing to offset rising borrowing costs.
6. BOTTOM LINE
Structural Advantage: A specialized portfolio of contiguous lab sites and deep institutional relationships that allow for flexible tenant expansion in high-demand biotech hubs. Bottom Line: Healthpeak is a high-yield transition play that remains a "show-me" story until the lab segment recovers and the Janus spinoff proves its value.
1. Top 5 Material Risks
- Macroeconomic Volatility: Higher interest rates, inflation, and labor shortages have increased borrowing, construction, and operating costs. These trends threaten Healthpeak Properties’s ability to execute accretive acquisitions and may force Healthpeak Properties to use high-cost labor alternatives, potentially causing operations to run below capacity.
- Healthcare Sector Concentration: Because Healthpeak Properties concentrates its investments in the healthcare sector, any downturn in this industry—or legislative efforts to limit REIT ownership of healthcare properties—would have a disproportionate adverse impact on Healthpeak Properties’s ability to maintain historical rental and occupancy rates.
- Tenant Financial Viability: Healthpeak Properties’s revenues depend on the ability of tenants and operators to meet financial obligations. Factors such as reduced Medicaid/Medicare funding, site-neutral payment initiatives, and bank failures could impair the liquidity of tenants, leading to lease rejections, bankruptcy, or the need to amend agreements on less favorable terms.
- Janus Living Offering: Healthpeak Properties faces risks that the pending Janus Living Offering may be delayed or fail to achieve intended benefits. Following the offering, Healthpeak Properties will retain a substantial majority interest and economic exposure to Janus Living, meaning shifts in the price of Janus Living common stock may adversely affect the value realized by Healthpeak Properties.
- Property-Specific Concentration: A significant portion of the lab portfolio (approximately 69% based on gross asset value as of December 31, 2025) is concentrated in California, exposing Healthpeak Properties to earthquake and wildfire risks. Similarly, approximately 69% of the life plan community portfolio is concentrated in Florida, exposing Healthpeak Properties to hurricane risks.
2. Company-Specific Risks
- RIDEA Structure Exposure: In senior housing properties managed under RIDEA structures, Healthpeak Properties directly bears operational risks, including occupancy rates and labor costs, with limited indemnification from operators except in cases of gross negligence or willful misconduct.
- Tax Protection Agreements: Healthpeak Properties is party to tax protection agreements that may make it economically prohibitive to sell certain properties, even if a sale would otherwise be in the best interest of stockholders, and may require Healthpeak Properties to maintain minimum debt levels.
- Structural Subordination: As a holding company, Healthpeak Properties relies on distributions from Healthpeak OP to pay dividends and liabilities; stockholder claims are structurally subordinated to all existing and future liabilities of Healthpeak OP and its subsidiaries.
- AI Integration Risks: Healthpeak Properties’s use of AI tools in investment and capital allocation decisions introduces risks of inaccuracy, bias, and cybersecurity threats, while tenants’ adoption of AI may lead to infrastructure requirements (such as increased power needs) that current buildings do not accommodate.
3. Regulatory/Legal Risks
- REIT Qualification: Failure to meet complex Internal Revenue Code provisions—such as the 95% gross income test or the 90% distribution requirement—could result in the loss of REIT status, subjecting Healthpeak Properties to corporate-level income taxes and reducing funds available for dividends.
- Healthcare Regulation: Tenants and operators are subject to extensive laws, including the Affordable Care Act and various state licensure requirements. Non-compliance can lead to loss of accreditation, denial of reimbursement, or closure of facilities, which would directly impact Healthpeak Properties’s rental income.
- Environmental Liability: As a property owner, Healthpeak Properties may be held liable for investigation and cleanup costs of hazardous substances at its properties, even if the contamination was caused by a previous owner or a tenant.
- Maryland Business Combination Act: Provisions in Healthpeak Properties’s charter and Maryland law, including the MBCA and a 90% voting requirement for certain business combinations, may delay or prevent a change of control or acquisition that could otherwise provide a premium price for stockholders.
4. Financial Impact Map
Macroeconomic Trends (Interest Rates/Inflation) → Operating Expenses/Interest Expense → Increased costs for borrowing, construction, labor, and utilities. Healthcare Sector Downturn → Rental Income → Reduced ability of tenants to maintain historical rental and occupancy rates. Tenant Bankruptcy/Lease Rejection → Rental Income → Unsecured claims limited by U.S. Bankruptcy Code statutory caps, which may be less than actual rent owed. Janus Living Offering → Investment Value/Stock Price → Economic exposure to Janus Living common stock price volatility and potential diversion of management attention. Natural Disasters (Earthquakes/Hurricanes) → Property Value/Capital Expenditures → Potential for uninsured losses or losses exceeding policy limits, and increased insurance premiums/deductibles.
Recent Filings
| Form | Filed | Period |
|---|---|---|
| 10-K | Feb 2026 | Dec 2025 |
| 8-K | Feb 2026 | — |
| 10-Q | Oct 2025 | Sep 2025 |
AI-extracted key facts from press releases and SEC filings. Significance 1–10.
Healthpeak Properties Raises 2026 Earnings Guidance Following Janus Living IPO and Q1 Results
- ▸Raised 2026 earnings guidance following Janus Living IPO completion
- ▸Janus Living IPO raised $880M in net proceeds
- ▸Healthpeak retains 81.6% equity ownership in Janus Living
- ▸Janus Living Q1 revenue +35% and Adjusted EBITDAre +42% YoY
- ▸Declared Q2 dividend of $0.305 per share, $1.22 annualized
Janus Living prices upsized IPO at $20 per share, raising $840 million
- ▸IPO priced at $20.00 per share for 42,000,000 shares
- ▸Total gross proceeds of $840 million
- ▸Healthpeak Properties to retain 83.6% voting interest post-IPO
- ▸Trading begins on NYSE under ticker JAN on March 20, 2026
- ▸Underwriters granted 30-day option for additional 6.3 million shares
Janus Living IPO Launches 37M Shares Priced Between $18 and $20
- ▸Janus Living IPO offering 37,000,000 shares at $18–$20 per share
- ▸Underwriters granted 30-day option for additional 5,550,000 shares
- ▸Healthpeak retains 85.3% economic interest in Janus Living post-IPO
- ▸Janus Living portfolio includes 34 communities with 10,422 units
- ▸Healthpeak to serve as external manager for $10 million annual fee
Janus Living Launches IPO of 37M Shares Priced Between $18 and $20
- ▸Janus Living launching IPO of 37,000,000 Class A-1 common shares
- ▸Expected IPO price range $18.00 to $20.00 per share
- ▸Healthpeak to retain 85.3% economic interest post-offering
- ▸Underwriters granted 30-day option for 5,550,000 additional shares
- ▸Janus Living to list on NYSE under ticker symbol JAN